Switch theme
Sign up to access all valuation multiples
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
1998
253
LTM Revenue $333M
LTM EBITDA $100M
$616M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ironwood Pharmaceuticals has a last 12-month revenue of $333M and a last 12-month EBITDA of $100M.
In the most recent fiscal year, Ironwood Pharmaceuticals achieved revenue of $351M and an EBITDA of $100M.
Ironwood Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ironwood Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $443M | $351M | XXX | XXX | XXX |
| Gross Profit | $411M | n/a | XXX | XXX | XXX |
| Gross Margin | 93% | NaN% | XXX | XXX | XXX |
| EBITDA | -$925M | $100M | XXX | XXX | XXX |
| EBITDA Margin | -209% | 29% | XXX | XXX | XXX |
| Net Profit | $175M | -$1.0B | XXX | XXX | XXX |
| Net Margin | 40% | -285% | XXX | XXX | XXX |
| Net Debt | n/a | $606M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Ironwood Pharmaceuticals's stock price is $1.
Ironwood Pharmaceuticals has current market cap of $105M, and EV of $616M.
See Ironwood Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $616M | $105M | XXX | XXX | XXX | XXX | $0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Ironwood Pharmaceuticals has market cap of $105M and EV of $616M.
Ironwood Pharmaceuticals's trades at 1.8x LTM EV/Revenue multiple, and 6.2x LTM EBITDA.
Analysts estimate Ironwood Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Ironwood Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $616M | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | 6.1x | XXX | XXX | XXX |
| P/E | 119.1x | XXX | XXX | XXX |
| P/E/Growth | 0.2x | XXX | XXX | XXX |
| EV/FCF | 6.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpIronwood Pharmaceuticals's NTM/LTM revenue growth is -12%
Ironwood Pharmaceuticals's revenue per employee for the last fiscal year averaged $1.4M, while opex per employee averaged $1.0M for the same period.
Over next 12 months, Ironwood Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Ironwood Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Ironwood Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -21% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -111% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 17% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.0M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 32% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 73% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ironwood Pharmaceuticals acquired XXX companies to date.
Last acquisition by Ironwood Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Ironwood Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Ironwood Pharmaceuticals founded? | Ironwood Pharmaceuticals was founded in 1998. |
| Where is Ironwood Pharmaceuticals headquartered? | Ironwood Pharmaceuticals is headquartered in United States of America. |
| How many employees does Ironwood Pharmaceuticals have? | As of today, Ironwood Pharmaceuticals has 253 employees. |
| Who is the CEO of Ironwood Pharmaceuticals? | Ironwood Pharmaceuticals's CEO is Mr. Thomas A. McCourt. |
| Is Ironwood Pharmaceuticals publicy listed? | Yes, Ironwood Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Ironwood Pharmaceuticals? | Ironwood Pharmaceuticals trades under IRWD ticker. |
| When did Ironwood Pharmaceuticals go public? | Ironwood Pharmaceuticals went public in 2010. |
| Who are competitors of Ironwood Pharmaceuticals? | Similar companies to Ironwood Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Ironwood Pharmaceuticals? | Ironwood Pharmaceuticals's current market cap is $105M |
| What is the current revenue of Ironwood Pharmaceuticals? | Ironwood Pharmaceuticals's last 12-month revenue is $333M. |
| What is the current EBITDA of Ironwood Pharmaceuticals? | Ironwood Pharmaceuticals's last 12-month EBITDA is $100M. |
| What is the current EV/Revenue multiple of Ironwood Pharmaceuticals? | Current revenue multiple of Ironwood Pharmaceuticals is 1.8x. |
| What is the current EV/EBITDA multiple of Ironwood Pharmaceuticals? | Current EBITDA multiple of Ironwood Pharmaceuticals is 6.2x. |
| What is the current revenue growth of Ironwood Pharmaceuticals? | Ironwood Pharmaceuticals revenue growth between 2023 and 2024 was -21%. |
| Is Ironwood Pharmaceuticals profitable? | Yes, Ironwood Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
